# Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

> **NCT04704505** · PHASE2 · RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 47 (estimated)

## Conditions studied

- Prostate Adenocarcinoma
- Metastatic Prostate Adenocarcinoma
- Castration-resistant

## Interventions

- **RADIATION:** radium-223
- **DRUG:** Bipolar Androgen Therapy (BAT)

## Key facts

- **NCT ID:** NCT04704505
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-28
- **Primary completion:** 2028-02
- **Final completion:** 2029-02
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04704505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04704505, "Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04704505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*